A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation.

Trial Profile

A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Immunoglobulins (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Acronyms SCIG-MG
  • Most Recent Events

    • 28 Apr 2017 Results (n=22) update on efficacy presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results (n=22) update on safety, feasibility, and pharmacokinetics presented at the 69th Annual Meeting of the American Academy of Neurology
    • 03 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top